We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge, Massachusetts.
- Recent RLAY Stock Price: $16.48
- Yearly Gain for RLAY stock: -56.11%
- Market Cap for RLAY stock: $1.78B
- P/E Ratio for RLAY stock: -4.137
Will RLAY's stock price go up? Is there an accurate RLAY stock forecast available?
TipRanks.com reports that Relay Therapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $36.40. The target pricing ranges from a high RLAY forecast of $47.00 down to a low forecast of $13.00. Relay Therapeutics (RLAY)’s last closing stock price was $16.48 which would put the average price target at 120.87% upside.
In addition, TradingView issued a Sell rating for RLAY stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on RLAY stock.
Other analysts covering RLAY include:
- Robert Burns of H.C. Wainwright issued a Buy rating with the price target of $ 47 on 1 day ago
- Gaurav Goparaju of Berenberg Bank issued a Buy rating with the price target of $ 45 on 2 days ago
- Akash Tewari of Jefferies issued a Sell rating with the price target of $ 13 on 3 weeks ago
- Salveen Richter of Goldman Sachs issued a Buy rating with the price target of $ 42 on 1 month ago
If you are wondering if RLAY is a good stock to buy, here are 3rd party ratings for RLAY stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 41% (102 out of 251)
What is the sentiment on the street regarding Relay Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for RLAY stock: Very Bullish
- Blogger Consensus for RLAY stock: Bullish
- Media Buzz for RLAY stock: Very High
- Insider Signal for RLAY stock: Negative
- Investor Sentiment for RLAY stock: Very Negative
- Hedge Fund signal for RLAY stock: Neutral
The stock market is extremely volatile, and you need to do your own research on RLAY stock including scouring the social networks like RLAY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RLAY stock chart >>
Summary: Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
- Recent AXSM Stock Price: $37.13
- Yearly Gain for AXSM stock: -45.51%
- Market Cap for AXSM stock: $1.48B
- P/E Ratio for AXSM stock: -10.208
Will AXSM's stock price go up? Is there an accurate AXSM stock forecast available?
TipRanks.com reports that Axsome Therapeutics currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $56.56. The target pricing ranges from a high AXSM forecast of $117.00 down to a low forecast of $27.00. Axsome Therapeutics (AXSM)’s last closing stock price was $37.13 which would put the average price target at 52.63% upside.
In addition, TradingView issued a Buy rating for AXSM stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AXSM stock.
Other analysts covering AXSM include:
- Jason Gerberry of Bank of America Securities issued a Sell rating with the price target of $ 28 on 16 hours ago
- Joseph Thome of Cowen & Co. issued a Buy rating with the price target of n/a on 16 hours ago
- Chris Howerton of Jefferies issued a Buy rating with the price target of $ 77 on 1 day ago
- Vamil Divan of Mizuho Securities issued a Buy rating with the price target of $ 49 on 2 days ago
If you are wondering if AXSM is a good stock to buy, here are 3rd party ratings for AXSM stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 37% (93 out of 251)
What is the sentiment on the street regarding Axsome Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for AXSM stock: Very Bullish
- Blogger Consensus for AXSM stock: Bullish
- Media Buzz for AXSM stock: Very High
- Insider Signal for AXSM stock: ―
- Investor Sentiment for AXSM stock: Neutral
- Hedge Fund signal for AXSM stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on AXSM stock including scouring the social networks like AXSM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AXSM stock chart >>
Summary: Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California.
- Recent KZR Stock Price: $7.76
- Yearly Gain for KZR stock: 49.64%
- Market Cap for KZR stock: $500.85M
- P/E Ratio for KZR stock: -7.926
Will KZR's stock price go up? Is there an accurate KZR stock forecast available?
TipRanks.com reports that Kezar Life Sciences currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.67. The target pricing ranges from a high KZR forecast of $22.00 down to a low forecast of $17.00. Kezar Life Sciences (KZR)’s last closing stock price was $7.76 which would put the average price target at 153.48% upside.
In addition, TradingView issued a Buy rating for KZR stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KZR stock.
Other analysts covering KZR include:
- Derek Archila of Wells Fargo issued a Buy rating with the price target of $ 17 on 1 day ago
- Catherine Novack of JonesTrading issued a Buy rating with the price target of n/a on 1 day ago
- Ram Selvaraju of H.C. Wainwright issued a Buy rating with the price target of $ 22 on 1 day ago
- Matt Phipps of William Blair issued a Buy rating with the price target of n/a on 1 month ago
If you are wondering if KZR is a good stock to buy, here are 3rd party ratings for KZR stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 37% (93 out of 251)
What is the sentiment on the street regarding Kezar Life Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for KZR stock: Very Bullish
- Blogger Consensus for KZR stock: ―
- Media Buzz for KZR stock: Very High
- Insider Signal for KZR stock: ―
- Investor Sentiment for KZR stock: Very Positive
- Hedge Fund signal for KZR stock: Positive
The stock market is extremely volatile, and you need to do your own research on KZR stock including scouring the social networks like KZR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for KZR stock chart >>
Summary: Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.
- Recent MDNA Stock Price: $1.14
- Yearly Gain for MDNA stock: -57.38%
- Market Cap for MDNA stock: $65.44M
- P/E Ratio for MDNA stock: -3.731
Will MDNA's stock price go up? Is there an accurate MDNA stock forecast available?
TipRanks.com reports that Medicenna Therapeutics Corp currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $7.95. The target pricing ranges from a high MDNA forecast of $11.00 down to a low forecast of $3.89. Medicenna Therapeutics Corp (MDNA)’s last closing stock price was $1.14 which would put the average price target at 597.36% upside.
In addition, TradingView issued a Neutral rating for MDNA stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MDNA stock.
Other analysts covering MDNA include:
- Matthew Biegler of Oppenheimer issued a Buy rating with the price target of $ 10 on 1 week ago
- Prasath Pandurangan of Bloom Burton issued a Buy rating with the price target of $ 11 on 1 week ago
- Jason McCarthy of Maxim Group issued a Buy rating with the price target of $ 4 on 1 week ago
- Kumaraguru Raja of Brookline Capital Markets issued a Buy rating with the price target of $ 10.88 on 1 month ago
If you are wondering if MDNA is a good stock to buy, here are 3rd party ratings for MDNA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Medicenna Therapeutics Corp? (Current ratings compiled by TipRanks.com)
- News Sentiment for MDNA stock: Very Bullish
- Blogger Consensus for MDNA stock: Bullish
- Media Buzz for MDNA stock: Low
- Insider Signal for MDNA stock: ―
- Investor Sentiment for MDNA stock: ―
- Hedge Fund signal for MDNA stock: No Signal
The stock market is extremely volatile, and you need to do your own research on MDNA stock including scouring the social networks like MDNA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MDNA stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================